vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

vTv Therapeutics Inc. (NASDAQ:VTVT) has received a consensus rating of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $53.00.

Several equities research analysts recently commented on the company. BTIG Research reaffirmed a “buy” rating and issued a $49.00 price target on shares of vTv Therapeutics in a report on Wednesday, March 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of vTv Therapeutics in a report on Friday, March 27th. Evercore initiated coverage on vTv Therapeutics in a report on Thursday, March 12th. They issued an “outperform” rating and a $44.00 price target for the company. Zacks Research raised vTv Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. Finally, Wall Street Zen raised vTv Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday.

vTv Therapeutics Price Performance

NASDAQ VTVT opened at $35.69 on Friday. The stock has a market capitalization of $140.62 million, a PE ratio of -38.38 and a beta of 0.26. The business has a 50 day simple moving average of $35.95 and a two-hundred day simple moving average of $34.08. vTv Therapeutics has a 1-year low of $14.00 and a 1-year high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 EPS for the quarter, beating the consensus estimate of $0.21 by $1.44. The company had revenue of $36.84 million during the quarter, compared to analyst estimates of $20.00 million. On average, analysts anticipate that vTv Therapeutics will post -2.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Baker BROS. Advisors LP boosted its holdings in vTv Therapeutics by 52.4% in the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after purchasing an additional 51,000 shares during the period. Geode Capital Management LLC boosted its holdings in vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after purchasing an additional 12,896 shares during the period. 683 Capital Management LLC purchased a new position in vTv Therapeutics in the fourth quarter valued at $731,000. Finally, Goldman Sachs Group Inc. purchased a new position in vTv Therapeutics in the fourth quarter valued at $221,000. 17.51% of the stock is currently owned by hedge funds and other institutional investors.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.